Shareholder Alert: Ademi LLP investigates whether Mirati Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myers Squibb

MILWAUKEE, Oct. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating Mirati (Nasdaq: MRTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myers Squibb.

Click here to learn how to join the action https://www.ademilaw.com/case/mirati-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, Mirati stockholders are expected to receive only $58.00 per share in cash, for a total equity value of $4.8 billion. Mirati stockholders will also receive one non-tradeable Contingent Value Right for each Mirati share held, potentially worth $12.00 per share in cash. The transaction agreement unreasonably limits competing transactions for Mirati by imposing a significant penalty if Mirati accepts a competing bid. Mirati insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Mirati's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Mirati common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/mirati-therapeutics-inc.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP